<DOC>
	<DOCNO>NCT01332370</DOCNO>
	<brief_summary>This retrospective database study analyze resource utilization cost associate sitagliptin ( STG ) comparison rosiglitazone ( RSG ) add metformin ( MET ) monotherapy among adults diagnosis diabetes continuously enrol large US healthcare plan .</brief_summary>
	<brief_title>Prescription Patterns , Resource Utilization &amp; Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs v Rosiglitazone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Continuously enrol health insurance plan ensure complete claim coverage At least 1 claim diagnosis diabetes ( ICD9 250.xx ) Aged 18 year old index date At least 6 month baseline period prior index date At least 1 claim MET baseline period At least 180 day continuous therapy RSG+MET STG+MET index date At least 1 claim insulin sulfonylurea baseline period At least 1 claim diagnosis congestive heart failure baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Retrospective</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Cost Analysis</keyword>
	<keyword>Rosiglitazone</keyword>
	<keyword>Sitagliptin</keyword>
</DOC>